These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19430096)

  • 1. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
    Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
    Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
    Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
    Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
    J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIVABIC trial].
    Halfon P; Pénaranda G; Cacoub P
    Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S113-7. PubMed ID: 19375039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
    Martín-Carbonero L; Tuma P; Vispo E; Medrano J; Labarga P; González-Lahoz J; Barreiro P; Soriano V
    J Viral Hepat; 2011 Aug; 18(8):542-8. PubMed ID: 20819149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Halfon P
    J Hepatol; 2008 May; 48(5):765-73. PubMed ID: 18314219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
    Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
    J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
    Wu L; Kottilil S; Lempicki R; Yang J; McLaughlin M; Hu Z; Koratich C; Reitano KN; Rehm CA; Masur H; Wood B; Kleiner DE; Polis MA
    AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1091-8. PubMed ID: 17147494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
    Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
    Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
    Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
    J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.